Madrigal Pharmaceuticals (MDGL)

• Market cap: $9.63B
• 1 day: -1.65%
• 5 days: -0.68%
• 1 month: 20.4%
• 3 months: 45.43%
• 6 months: 32.05%
• Year to date: 37.75%
• 1 year: 84.11%
• 5 years: 303.72%
• 10 years: 517.46%
• Sector: Healthcare
• Industry: Biotechnology

About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Employees: 528

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

89% more call options, than puts

Call options by funds: $294M | Put options by funds: $155M

0% more funds holding in top 10

Funds holding in top 10: 12 [Q1] → 12 (+0) [Q2]

0.92% less ownership

Funds ownership: 106.97% [Q1] → 106.04% (-0.92%) [Q2]

4% less repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 109

4% less funds holding

Funds holding: 317 [Q1] → 303 (-14) [Q2]

9% less capital invested

Capital invested by funds: $7.82B [Q1] → $7.13B (-$690M) [Q2]

22% less first-time investments, than exits

New positions opened: 40 | Existing positions closed: 51

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $485
• Avg. target: $518
• High target: $554

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity Edward Nash	$526	Buy Maintained	12 Sep 2025
HC Wainwright & Co. Andrew S. Fein	$500	Buy Assumed	4 Sep 2025
TD Cowen Ritu Baral	$554	Buy Maintained	26 Aug 2025
JMP Securities Jonathan Wolleben	$485	Market Outperform Maintained	20 Aug 2025
UBS Eliana Merle	$523	Buy Maintained	12 Aug 2025